Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma

Inclusion Criteria: * Age ≥ 18 years * Histological confirmation of esophageal or gastroesophageal junction adenocarcinoma, American Joint Committee on Cancer (AJCC) 8th edition stage T1-4N0-3M0 * Candidate for trimodality therapy: neoadjuvant chemo (immuno) therapy, chemoradiation, and esophagectomy * Surgical consultation has confirmed that patient is an appropriate candidate for esophagectomy * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1 * Negative pregnancy test done ≤ 7 days prior to chemotherapy, for women of childbearing potential only * Ability to provide written informed consent and complete questionnaire(s) by themselves or with assistance * Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study) * Willing to provide blood and tissue samples for correlative research purposes Exclusion Criteria: * Clinical or biopsy-proven distant metastatic disease (AJCC 8th edition stage TanyNanyM1) * Cervical or upper esophageal tumor * Prior chemotherapy or radiotherapy for esophageal cancer or history of radiotherapy to the thorax * Co-morbid systemic illnesses or other severe concurrent disease which, in the judgement of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with proper assessment of adverse events * Receiving any investigational agent which would be considered as a treatment for the primary neoplasm or other active malignancy ≤ 1 year prior to registration that is considered by the investigator to interfere with the current treatment or measurement of outcomes * Any of the following: * Pregnant women * Nursing women * Men or women of childbearing potential who are unwilling to employ adequate contraception